Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTPRF | P10586 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11663201 | 0.85 | AKR1B1 (0.61) | AKR1B1MAPK14ALDH1A1SMN1; SMN2PDK2 | |
| SCHEMBL8880119 | 0.84 | AKR1B1 (0.66) | AKR1B1MAPK14LMNAPOLBPTPRC | |
| SCHEMBL11567084 | 0.83 | AKR1B1 (0.54) | AKR1B1MAPK14ALDH1A1SMN1; SMN2PTPRC | |
| SCHEMBL11569877 | 0.83 | AKR1B1 (0.61) | AKR1B1MAPK14ALDH1A1PTPRCL3MBTL1 | |
| SCHEMBL11566798 | 0.82 | AKR1B1 (0.52) | AKR1B1MAPK14ALDH1A1LMNAPOLB | |
| SCHEMBL8137823 | 0.81 | ALDH1A1 (0.40) | AKR1B1ALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL8142034 | 0.80 | SRD5A1 (0.56) | MAPK14ALDH1A1PTPRCKDM4EHPGD | |
| SCHEMBL11566471 | 0.80 | AKR1B1 (0.60) | AKR1B1MAPK14ALDH1A1KDM4ETRPA1 | |
| SCHEMBL11754579 | 0.80 | AKR1B1 (0.60) | AKR1B1MAPK14PTPRC | |
| SCHEMBL11824727 | 0.79 | AKR1B1 (0.74) | AKR1B1MAPK14ALDH1A1SMN1; SMN2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-8163730-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-04-24 | — | — | US | disclosed |
| US-7964631-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-α | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-23 | — | — | US | disclosed |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-02 | — | — | US | disclosed |
| US-7834001-B2 | N-(10,10-Dioxo-10,11-dihydro-5-oxa-10-lambda*6*-thia-dibenzo[a.d]cycloheptene-8-carbonyl)-guanidine; tumor necrosis factor inhibitors; sodium-proton exchange inhibitors for treatment of organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-7834052-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| US-20070299050-A1 | Fused Tricyclic Compounds as Inhibitors of Tumor Necrosis Factor-Alpha | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| EP-1812420-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812419-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051476-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006051477-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
| EP-0549352-B1 | Tricyclic compounds as angiotensin II antagonists | KYOWA HAKKO KOGYO KK (JP) | 2000-03-01 | — | — | EP | disclosed |
| US-5478840-A | Imidazo(4,5-b)pyridine derivatives used as antagonism to angiotensin ii receptors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5378701-A | Angiotensin II inhibitors; hypotensive agents; congestive heart and kidney failure; glaucoma | KYOWA HAKKO KOGYO (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0549352-A2 | Tricyclic compounds as angiotensin II antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | AKR1B1 389/4885MAPK14 2429/4885ALDH1A1 3478/4885 |
| US-20070299050-A1 | Fused Tricyclic Compounds as Inhibitors of Tumor Necrosis Factor-Alpha | CD40, TNFRSF1A, OXER1 | AKR1B1 421/4885MAPK14 2600/4885ALDH1A1 3592/4885 |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | ATP2A1, ATP2A3, KCNN4 | AKR1B1 123/4885MAPK14 2826/4885ALDH1A1 1222/4885 |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | ATP2A1, ATP2A3, KCNN4 | AKR1B1 123/4885MAPK14 2826/4885ALDH1A1 1222/4885 |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | AKR1B1 421/4885MAPK14 2600/4885ALDH1A1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.